Atea Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Business Update
Atea reported cash and investments of $219.5 million at the end of Q2 2026, down from $301.8 million at year-end 2025, with a net loss of $0.41 per share for the quarter. The company provided an update on its Phase 3 C-BEYOND trial, where BEM/RZR achieved a 93.9% sustained virologic response rate, meeting the primary endpoint of non-inferiority compared to Epclusa. Atea plans to submit a New Drug Application to the FDA in the second quarter of 2027.
Key figures
- Net loss
- $32.9 million
- Ga expenses
- $7.0 million
- Rd expenses
- $28.2 million
- Cash position
- $219.5 million
- Svr rate bem rzr
- 93.9%
- Svr rate sof vel
- 94.8%
AI analysis
Red flags1 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.